ReP USP - Resultado da busca

Trabalho de evento-resumo periodico
Molecular characterization of clinical response and relapse in patients with IDH1m ND-AML treated with Ivo+AZA in the aGILE study (2022)
Döhner, Hartmut; Marchione, Dylan M.; Choe, Sung; Montesinos, Pau; Recher, Christian; Vives, Susana; Zarzycka, Ewa; Wang, Jianxiang; Cerchione, Claudio; Heuser, Michael; Calado, Rodrigo Tocantins ; Schuh, Andre C.; Yeh, Su-Peng; De La Fuente, Adolfo; Hui, Jianan; Patel, Prapti; Gianolio, Diego; Daigle, Scott R.; DiNardo, Courtney D.; Botton, Stephane de
Source: Blood. Conference titles: ASH Annual Meeting and Exposition. Unidade: FMRP
Assunto: MOLÉCULA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DÖHNER, Hartmut et al. Molecular characterization of clinical response and relapse in patients with IDH1m ND-AML treated with Ivo+AZA in the aGILE study. Blood. Amsterdam: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2022-159473. Acesso em: 01 maio 2026. , 2022
APA
Döhner, H., Marchione, D. M., Choe, S., Montesinos, P., Recher, C., Vives, S., et al. (2022). Molecular characterization of clinical response and relapse in patients with IDH1m ND-AML treated with Ivo+AZA in the aGILE study. Blood. Amsterdam: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1182/blood-2022-159473
NLM
Döhner H, Marchione DM, Choe S, Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Cerchione C, Heuser M, Calado RT, Schuh AC, Yeh S-P, De La Fuente A, Hui J, Patel P, Gianolio D, Daigle SR, DiNardo CD, Botton S de. Molecular characterization of clinical response and relapse in patients with IDH1m ND-AML treated with Ivo+AZA in the aGILE study [Internet]. Blood. 2022 ; 140( suppl. 1): 539-542.[citado 2026 maio 01 ] Available from: https://doi.org/10.1182/blood-2022-159473
Vancouver
Döhner H, Marchione DM, Choe S, Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Cerchione C, Heuser M, Calado RT, Schuh AC, Yeh S-P, De La Fuente A, Hui J, Patel P, Gianolio D, Daigle SR, DiNardo CD, Botton S de. Molecular characterization of clinical response and relapse in patients with IDH1m ND-AML treated with Ivo+AZA in the aGILE study [Internet]. Blood. 2022 ; 140( suppl. 1): 539-542.[citado 2026 maio 01 ] Available from: https://doi.org/10.1182/blood-2022-159473
Trabalho de evento-resumo periodico
Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine (2022)
Botton, Stephane de; Choe, Sung; Marchione, Dylan M.; Montesinos, Pau; Recher, Christian; Vives Polo, Susana; Zarzycka, Ewa; Wang, Jianxiang; Bertani, Giambattista; Heuser, Michael; Calado, Rodrigo Tocantins ; Schuh, Andre C.; Yeh, Su-Peng; Hui, Jianan; Pandya, Shuchi Sumant; Gianolio, Diego; Daigle, Scott; Dinardo, Courtney Denton; Döhner, Hartmut
Source: Journal of Clinical Oncology. Conference titles: Annual Meeting of American Society of Clinical Oncology (ASCO). Unidade: FMRP
Subjects: LEUCEMIA MIELOIDE, MOLÉCULA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOTTON, Stephane de et al. Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1200/JCO.2022.40.16_suppl.7019. Acesso em: 01 maio 2026. , 2022
APA
Botton, S. de, Choe, S., Marchione, D. M., Montesinos, P., Recher, C., Vives Polo, S., et al. (2022). Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1200/JCO.2022.40.16_suppl.7019
NLM
Botton S de, Choe S, Marchione DM, Montesinos P, Recher C, Vives Polo S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh S-P, Hui J, Pandya SS, Gianolio D, Daigle S, Dinardo CD, Döhner H. Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine [Internet]. Journal of Clinical Oncology. 2022 ; 40( 16): 1 .[citado 2026 maio 01 ] Available from: https://doi.org/10.1200/JCO.2022.40.16_suppl.7019
Vancouver
Botton S de, Choe S, Marchione DM, Montesinos P, Recher C, Vives Polo S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh S-P, Hui J, Pandya SS, Gianolio D, Daigle S, Dinardo CD, Döhner H. Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine [Internet]. Journal of Clinical Oncology. 2022 ; 40( 16): 1 .[citado 2026 maio 01 ] Available from: https://doi.org/10.1200/JCO.2022.40.16_suppl.7019
Trabalho de evento-resumo periodico
AGILE: a global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation (2021)
Montesinos, Pau; Recher, Christian; Vives, Susana; Zarzycka, Ewa; Wang, Jianxiang; Bertani, Giambattista; Heuser, Michael; Calado, Rodrigo Tocantins ; Schuh, Andre C.; Yeh, Su-Peng; Daigle, Scott R.; Hui, Jianan; Zhang, Vickie; Pandya, Shuchi S.; Gianolio, Diego; Botton, Stephane de; Döhner, Hartmut
Source: Blood. Conference titles: ASH Annual Meeting Abstracts. Unidade: FMRP
Subjects: LEUCEMIA MIELOIDE, MUTAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MONTESINOS, Pau et al. AGILE: a global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2021-147805. Acesso em: 01 maio 2026. , 2021
APA
Montesinos, P., Recher, C., Vives, S., Zarzycka, E., Wang, J., Bertani, G., et al. (2021). AGILE: a global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1182/blood-2021-147805
NLM
Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh S-P, Daigle SR, Hui J, Zhang V, Pandya SS, Gianolio D, Botton S de, Döhner H. AGILE: a global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation [Internet]. Blood. 2021 ; 138 697-697.[citado 2026 maio 01 ] Available from: https://doi.org/10.1182/blood-2021-147805
Vancouver
Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh S-P, Daigle SR, Hui J, Zhang V, Pandya SS, Gianolio D, Botton S de, Döhner H. AGILE: a global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation [Internet]. Blood. 2021 ; 138 697-697.[citado 2026 maio 01 ] Available from: https://doi.org/10.1182/blood-2021-147805

USP Schools

ReP

Filtros

Authors

Non normalized affiliation

Countries of institutions of collaboration